Short Interest in Grifols, S.A. (NASDAQ:GRFS) Decreases By 8.5%

Grifols, S.A. (NASDAQ:GRFS) saw a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 5,060,000 shares, a drop of 8.5% from the August 31st total of 5,530,000 shares. Based on an average daily volume of 1,730,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 2.0% of the shares of the company are sold short.

Grifols Trading Down 0.7 %

Shares of Grifols stock traded down $0.06 during trading hours on Tuesday, hitting $8.82. 355,301 shares of the company were exchanged, compared to its average volume of 2,074,320. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 0.80. The business has a 50-day moving average of $8.25 and a 200-day moving average of $7.46. Grifols has a 1 year low of $5.30 and a 1 year high of $12.15.

Grifols (NASDAQ:GRFS) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The firm had revenue of $1.96 billion for the quarter. Grifols had a return on equity of 1.73% and a net margin of 0.90%. On average, equities research analysts expect that Grifols will post 0.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Grifols

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cohen Investment Advisors LLC purchased a new stake in shares of Grifols in the first quarter valued at $80,000. AQR Capital Management LLC purchased a new stake in shares of Grifols during the 2nd quarter worth about $89,000. Morningstar Investment Services LLC acquired a new stake in Grifols during the 4th quarter worth approximately $186,000. Cetera Advisors LLC purchased a new stake in Grifols during the first quarter worth approximately $147,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Grifols by 66.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 23,461 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 9,350 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.